• Something wrong with this record ?

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

HKG. Garelius, T. Bagguley, A. Taylor, P. Fenaux, D. Bowen, A. Symeonidis, M. Mittelmann, R. Stauder, J. Čermák, G. Sanz, S. Langemeijer, L. Malcovati, U. Germing, L. Sanhes, M. d'Aveni, D. Culligan, I. Kotsianidis, KA. Koinig, C. van Marrewijk,...

. 2025 ; 12 (2) : e128-e137. [pub] -

Language English Country England, Great Britain

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc25009999

BACKGROUND: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive red blood cell transfusion (RBCT). In this study, with a longer follow up time and more patients included, we aimed to assess long-term effects on survival and health-related quality of life (HRQoL) of exposure to ESAs with or without RBCT in patients with lower risk myelodysplastic syndromes. METHODS: The EUMDS Registry is a non-interventional, longitudinal, real-world registry prospectively enrolling newly diagnosed patients older than 18 years with lower risk (International Prognostic Scoring System low or intermediate-1) myelodysplastic syndromes from 16 European countries and Israel. The analysis was restricted to patients with haemoglobin concentrations less than 100 g/L enrolled between Jan 1, 2008, and July 1, 2019, with last censoring of data on Dec 31, 2021. Patient management was recorded every 6 months, including treatment, transfusions, and HRQoL. ESA treatment followed local guidelines. The patients were separated into four groups at each study visit: no ESA or RBCT, ESA only, ESA plus RBCT, and RBCT only. The data were analysed longitudinally over time according to ESA and RBCT status during each 6-month interval, using propensity score matching. The main outcomes were median overall survival and leukaemia-free survival, and HRQoL. This study is registered with ClinicalTrials.gov, NCT00600860, as is ongoing. FINDINGS: 2448 patients (the ESA-unexposed group [n=1265] and ESA-exposed group [n=1183]) were diagnosed before July 1, 2019; 1520 (62·1%) were male and 928 (37·9%) were female. Median follow-up time was 3·9 years (IQR 1·6-6·5). After applying eligibility criteria and propensity matching, there were 426 patients in the ESA-unexposed group and 744 patients in the ESA-exposed group. Median overall survival in the ESA exposed group was 44·9 months (95% CI 40·2-50·5) compared with 34·8 months (28·6-39·2) in the ESA unexposed group; the absolute difference was 10·1 months (95% CI 2·2-18·0; hazard ratio [HR] 0·70 [95% CI 0·59-0·83]; p<0·0001). Patients without RBCT in the presence or absence of ESA exposure maintained significantly better HRQoL than those with RBCT, irrespective of ESA exposure (linear mixed effect model of EQ-5d-3L index score, RBCT coefficient -0·04 [95% CI -0·06 to 0·03], p<0·0001; linear mixed effect model of VAS, -4·57 [-6·02 to -3·13], p<0·0001). INTERPRETATION: ESA treatment in patients with lower risk myelodysplastic syndromes significantly improves overall survival when started before or early after the onset of regular transfusion therapy. Avoiding RBCT is associated with significantly better HRQoL. FUNDING: H2020 European Research Council, Novartis Pharmacy B V Oncology Europe, Amgen, BMS/Celgene International, Janssen Pharmaceutica, Takeda Pharmaceuticals International, and Gilead Sciences.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009999
003      
CZ-PrNML
005      
20250429135439.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2352-3026(24)00350-8 $2 doi
035    __
$a (PubMed)39909656
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Garelius, Hege Kristin Gravdahl $u Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: hege.garelius@vgregion.se
245    10
$a Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study / $c HKG. Garelius, T. Bagguley, A. Taylor, P. Fenaux, D. Bowen, A. Symeonidis, M. Mittelmann, R. Stauder, J. Čermák, G. Sanz, S. Langemeijer, L. Malcovati, U. Germing, L. Sanhes, M. d'Aveni, D. Culligan, I. Kotsianidis, KA. Koinig, C. van Marrewijk, S. Crouch, T. deWitte, A. Smith, E. Hellström-Lindberg
520    9_
$a BACKGROUND: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive red blood cell transfusion (RBCT). In this study, with a longer follow up time and more patients included, we aimed to assess long-term effects on survival and health-related quality of life (HRQoL) of exposure to ESAs with or without RBCT in patients with lower risk myelodysplastic syndromes. METHODS: The EUMDS Registry is a non-interventional, longitudinal, real-world registry prospectively enrolling newly diagnosed patients older than 18 years with lower risk (International Prognostic Scoring System low or intermediate-1) myelodysplastic syndromes from 16 European countries and Israel. The analysis was restricted to patients with haemoglobin concentrations less than 100 g/L enrolled between Jan 1, 2008, and July 1, 2019, with last censoring of data on Dec 31, 2021. Patient management was recorded every 6 months, including treatment, transfusions, and HRQoL. ESA treatment followed local guidelines. The patients were separated into four groups at each study visit: no ESA or RBCT, ESA only, ESA plus RBCT, and RBCT only. The data were analysed longitudinally over time according to ESA and RBCT status during each 6-month interval, using propensity score matching. The main outcomes were median overall survival and leukaemia-free survival, and HRQoL. This study is registered with ClinicalTrials.gov, NCT00600860, as is ongoing. FINDINGS: 2448 patients (the ESA-unexposed group [n=1265] and ESA-exposed group [n=1183]) were diagnosed before July 1, 2019; 1520 (62·1%) were male and 928 (37·9%) were female. Median follow-up time was 3·9 years (IQR 1·6-6·5). After applying eligibility criteria and propensity matching, there were 426 patients in the ESA-unexposed group and 744 patients in the ESA-exposed group. Median overall survival in the ESA exposed group was 44·9 months (95% CI 40·2-50·5) compared with 34·8 months (28·6-39·2) in the ESA unexposed group; the absolute difference was 10·1 months (95% CI 2·2-18·0; hazard ratio [HR] 0·70 [95% CI 0·59-0·83]; p<0·0001). Patients without RBCT in the presence or absence of ESA exposure maintained significantly better HRQoL than those with RBCT, irrespective of ESA exposure (linear mixed effect model of EQ-5d-3L index score, RBCT coefficient -0·04 [95% CI -0·06 to 0·03], p<0·0001; linear mixed effect model of VAS, -4·57 [-6·02 to -3·13], p<0·0001). INTERPRETATION: ESA treatment in patients with lower risk myelodysplastic syndromes significantly improves overall survival when started before or early after the onset of regular transfusion therapy. Avoiding RBCT is associated with significantly better HRQoL. FUNDING: H2020 European Research Council, Novartis Pharmacy B V Oncology Europe, Amgen, BMS/Celgene International, Janssen Pharmaceutica, Takeda Pharmaceuticals International, and Gilead Sciences.
650    _2
$a lidé $7 D006801
650    12
$a kvalita života $7 D011788
650    12
$a myelodysplastické syndromy $x farmakoterapie $x mortalita $x terapie $x komplikace $7 D009190
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a hematinika $x terapeutické užití $7 D006397
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a transfuze erytrocytů $x škodlivé účinky $7 D017707
650    _2
$a registrace $7 D012042
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kohortové studie $7 D015331
650    _2
$a longitudinální studie $7 D008137
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Bagguley, Timothy $u Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
700    1_
$a Taylor, Adele $u Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
700    1_
$a Fenaux, Pierre $u Hôpital Saint-Louis, Paris, France
700    1_
$a Bowen, David $u Leeds Teaching Hospitals NHS Trust, Leeds, UK
700    1_
$a Symeonidis, Argiris $u University of Patras School of Medicine, Patras, Greece
700    1_
$a Mittelmann, Moshe $u Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel
700    1_
$a Stauder, Reinhard $u Medizinische Universität Innsbruck, Innsbruck, Austria; Department of Public Health, Health Services Research, and Health Technology Assessment, UMIT Tirol-The Tyrolean Private University, Hall in Tirol, Austria
700    1_
$a Čermák, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Sanz, Guillermo $u Consorcio Hospital General Universitario de Valencia, Valencia, Spain
700    1_
$a Langemeijer, Saskia $u Radboud University Medical Center, Nijmegen, Netherlands
700    1_
$a Malcovati, Luca $u University of Pavia & IRCCS Policlinico San Matteo, Pavia, Italy
700    1_
$a Germing, Ulrich $u Universitätsklinikum Düsseldorf, Düsseldorf, Germany
700    1_
$a Sanhes, Laurence $u Centre Hospitalier de Perpignan, Perpignan, France
700    1_
$a d'Aveni, Maud $u Centre Hospitalier Régional Universitaire de Nancy Hôpitaux de Brabois, Vandèuvre-lès-Nancy, France
700    1_
$a Culligan, Dominic $u Aberdeen Royal Infirmary, Aberdeen, UK
700    1_
$a Kotsianidis, Ioannis $u General University Hospital of Alexandroupolis, Alexandroupoli, Greece
700    1_
$a Koinig, Karin A $u Medizinische Universität Innsbruck, Innsbruck, Austria
700    1_
$a van Marrewijk, Corine $u Radboud University Medical Center, Nijmegen, Netherlands
700    1_
$a Crouch, Simon $u Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
700    1_
$a deWitte, Theo $u Radboud University Medical Center, Nijmegen, Netherlands
700    1_
$a Smith, Alexandra $u Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
700    1_
$a Hellström-Lindberg, Eva $u Karolinska Institute, Solna, Sweden
773    0_
$w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 12, č. 2 (2025), s. e128-e137
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39909656 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135435 $b ABA008
999    __
$a ok $b bmc $g 2311396 $s 1247080
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 12 $c 2 $d e128-e137 $e - $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options